

New Zealand Public Health Surveillance Report Volume 6 Issue 4

References

Pneumococcal Disease: Introduction of the vaccine Prevenar

1. Bogaert D, de Groot R., Hermans P.W.M. *Streptococcus pneumoniae* colonisation: the key to pneumococcal disease. *Lancet Infect Dis* 2004;4: 144-154.
2. Heffernan HM., Martin DR., Woodhouse RE., Morgan J., Blackmore TK. Invasive pneumococcal disease in New Zealand 1998-2005: capsular serotypes and antimicrobial resistance. *Epidemiol Infect* 2008;136: 352-359.
3. Voss L., Lennon D., Kara O., Ameratunga S., Martin D. Invasive pneumococcal disease in a pediatric population, Auckland, New Zealand. *Pediatric Infectious Disease Journal* 1994; 13: 873-878.
4. Obaro S.K. Confronting the pneumococcus: a target shift or bullet change? *Vaccine* 2001; 19: 1211-1217.
5. Haber M., Barskey A., Baughman W., Barker L., Whitney C.G., Shaw K.M., Orenstein W., Stephens D.S. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. *Vaccine* 2007;25: 5390-5398.
6. Martin D.R., Brett M.S. Pneumococi causing invasive disease in New Zealand, 1987-94: serogroup and serotype coverage and antibiotic resistances. *New Zealand Medical Journal* 1996;108:288-90.
7. Bogaert D., Hermans P.W.M., Adrian P.V., Rumke H.C., de Groot, R. Pneumococcal vaccines: and update on current strategies. *Vaccine* 2004; 22: 2209-2220
8. Oosterhuis-Kafeja F., Beutels P., Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). *Vaccine* 2007;25: 2194-2212.
9. Whitney C.G., Pilishvili T., Farley M.M., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. *Lancet* 2006;368: 1495-1502.